DE69615838T2 - Cyclische wirkstoff-vorläufer verbindungen von peptiden und peptid-nukleicsäuren mit verbesserter metabolischer stabilität und zellmembran permeabilität - Google Patents

Cyclische wirkstoff-vorläufer verbindungen von peptiden und peptid-nukleicsäuren mit verbesserter metabolischer stabilität und zellmembran permeabilität

Info

Publication number
DE69615838T2
DE69615838T2 DE69615838T DE69615838T DE69615838T2 DE 69615838 T2 DE69615838 T2 DE 69615838T2 DE 69615838 T DE69615838 T DE 69615838T DE 69615838 T DE69615838 T DE 69615838T DE 69615838 T2 DE69615838 T2 DE 69615838T2
Authority
DE
Germany
Prior art keywords
nucleic acids
cell membrane
peptide nucleic
membrane permeability
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69615838T
Other languages
English (en)
Other versions
DE69615838D1 (de
Inventor
T Borchardt
Teruna Siahaan
Sanjeev Gangwar
J Stella
Binghe Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kansas
Original Assignee
University of Kansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Kansas filed Critical University of Kansas
Publication of DE69615838D1 publication Critical patent/DE69615838D1/de
Application granted granted Critical
Publication of DE69615838T2 publication Critical patent/DE69615838T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/70—Enkephalins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69615838T 1995-04-25 1996-04-08 Cyclische wirkstoff-vorläufer verbindungen von peptiden und peptid-nukleicsäuren mit verbesserter metabolischer stabilität und zellmembran permeabilität Expired - Fee Related DE69615838T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/429,732 US5672584A (en) 1995-04-25 1995-04-25 Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability
PCT/US1996/004180 WO1997039024A1 (en) 1995-04-25 1996-04-08 Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability

Publications (2)

Publication Number Publication Date
DE69615838D1 DE69615838D1 (de) 2001-11-15
DE69615838T2 true DE69615838T2 (de) 2002-04-25

Family

ID=23704505

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69615838T Expired - Fee Related DE69615838T2 (de) 1995-04-25 1996-04-08 Cyclische wirkstoff-vorläufer verbindungen von peptiden und peptid-nukleicsäuren mit verbesserter metabolischer stabilität und zellmembran permeabilität

Country Status (9)

Country Link
US (1) US5672584A (de)
EP (1) EP0830372B1 (de)
JP (1) JPH11508275A (de)
AT (1) ATE206716T1 (de)
AU (1) AU702993B2 (de)
CA (1) CA2219151A1 (de)
DE (1) DE69615838T2 (de)
ES (1) ES2165492T3 (de)
WO (1) WO1997039024A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE80466B1 (en) * 1995-11-10 1998-07-29 Elan Corp Plc Peptides which enhance transport across tissues and methods of identifying and using the same
US6521737B1 (en) * 1995-11-10 2003-02-18 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
US6361938B1 (en) * 1996-11-08 2002-03-26 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
CA2312975C (en) 1997-12-17 2012-08-21 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US5965119A (en) * 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6030997A (en) * 1998-01-21 2000-02-29 Eilat; Eran Acid labile prodrugs
EP1574210B1 (de) 1999-02-26 2016-04-06 Novartis Vaccines and Diagnostics, Inc. Mikroemulsionen mit adsorbierten Makromolekülen
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US20020199218A1 (en) * 1999-08-19 2002-12-26 Daphne Goring Proline-rich extensin-like receptor kinases
DE19942624A1 (de) * 1999-08-28 2001-03-08 Chemotopix Gmbh Verfahren zur Herstellung von zyklischen Peptidomimetika
CA2364983A1 (en) * 2000-12-13 2002-06-13 John R. Coleman Nucleic acid molecules and polypeptides for catabolism of abscisic acid
AU2002251988A1 (en) * 2001-02-20 2002-09-04 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US20030114385A1 (en) * 2001-04-27 2003-06-19 Cathers Brian E. Viral enzyme activated prototoxophores and use of same to treat viral infections
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
EP1404324B2 (de) * 2001-06-11 2011-04-06 XenoPort, Inc. Prodrugs von gaba-analoga, zusammensetzungen und ihre verwendungszwecke
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
SI1515752T1 (sl) 2002-06-19 2009-06-30 Univ Health Network Aktivacija ACE2 za zdravljenje srčne, pljučne in ledvične bolezni in hipertenzije
CN107090025A (zh) * 2003-11-05 2017-08-25 达纳-法伯癌症研究所股份有限公司 稳定的α螺旋肽及其用途
US7534902B2 (en) * 2003-11-14 2009-05-19 Wisconsin Alumni Research Foundation Fluorescence assays with improved sensitivity
BRPI0517227B8 (pt) * 2004-11-04 2021-05-25 Xenoport Inc comprimido oral de liberação prolongada do ácido 1-{[alfa-isobutanoiloxietoxi)carbonil]amino metil}-1-cicloexano acético, e, uso do comprimido
NZ566022A (en) * 2005-07-28 2011-04-29 Vertex Pharma Caspase inhibitor prodrugs
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
US20080261893A1 (en) * 2006-02-24 2008-10-23 Denise Barbut Topical corneal analgesia using neurotensin receptor agonists and synergistic neurotensin combinations without delaying wound healing
TW200820963A (en) * 2006-07-28 2008-05-16 Xenoport Inc Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use
CA2677045C (en) 2007-01-31 2016-10-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
AU2008225100A1 (en) * 2007-03-12 2008-09-18 Mayo Foundation For Medical Education And Research Topical corneal analgesia using neurotensin receptor agonists and synergistic neurotensin combinations without delaying wound healing
CA2682174C (en) 2007-03-28 2021-04-06 President And Fellows Of Harvard College Stitched polypeptides
KR20100126361A (ko) * 2008-02-08 2010-12-01 에일러론 테라퓨틱스 인코포레이티드 치료용 펩티드유사 거대고리
US20110144303A1 (en) * 2008-04-08 2011-06-16 Aileron Therapeutics, Inc. Biologically Active Peptidomimetic Macrocycles
CN104961795A (zh) 2008-09-22 2015-10-07 爱勒让治疗公司 用于制备纯化的多肽组合物的方法
AU2010204648B2 (en) 2009-01-14 2016-09-01 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN102712675A (zh) 2009-09-22 2012-10-03 爱勒让治疗公司 拟肽大环化合物
WO2012021876A2 (en) 2010-08-13 2012-02-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN108929375A (zh) 2011-10-18 2018-12-04 爱勒让治疗公司 拟肽大环化合物
ES2817877T3 (es) 2012-02-15 2021-04-08 Aileron Therapeutics Inc Macrociclos peptidomiméticos
WO2013123267A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
JP6526563B2 (ja) 2012-11-01 2019-06-05 エイルロン セラピューティクス，インコーポレイテッド 二置換アミノ酸ならびにその調製および使用の方法
KR101695792B1 (ko) * 2014-09-04 2017-01-12 디오셀 주식회사 신규 세포막 투과 펩티드 및 생리활성 물질 전달체로서의 그의 용도
SG10201902594QA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
BR112017005736A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e formulações dos mesmos
CA2979847A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2017004548A1 (en) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN108368161A (zh) 2015-09-10 2018-08-03 艾瑞朗医疗公司 作为mcl-1调节剂的拟肽大环化合物
KR20190139890A (ko) * 2017-03-23 2019-12-18 트루코드 진 리페어, 인크. 직교로 보호된 에스테르 모이어티를 갖는 펩타이드 핵산(ｐｎａ) 단량체
EP3675961A1 (de) 2017-08-31 2020-07-08 University Of Dundee Leptinpeptide und deren verwendung zur behandlung von neurologischen erkrankungen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof

Also Published As

Publication number Publication date
ATE206716T1 (de) 2001-10-15
DE69615838D1 (de) 2001-11-15
EP0830372A1 (de) 1998-03-25
AU702993B2 (en) 1999-03-11
WO1997039024A1 (en) 1997-10-23
US5672584A (en) 1997-09-30
AU5433096A (en) 1997-11-07
EP0830372B1 (de) 2001-10-10
CA2219151A1 (en) 1997-10-23
ES2165492T3 (es) 2002-03-16
JPH11508275A (ja) 1999-07-21

Similar Documents

Publication Publication Date Title
DE69615838T2 (de) Cyclische wirkstoff-vorläufer verbindungen von peptiden und peptid-nukleicsäuren mit verbesserter metabolischer stabilität und zellmembran permeabilität
ATE259828T1 (de) Prosaposin und cytokinabhängige peptide als therapeutisch wirksame mittel
DE69428040D1 (de) Orale darreichungsform
RU95108217A (ru) Дефектный рекомбинантный аденовирус, линия клеток, фармацевтическая композиция
FR2738151B1 (fr) Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers
NO993258D0 (no) Peptid-lipidkonjugater, liposomer og liposomal legemiddelavlevering
DE69823055D1 (de) Abgabe von polyethylene glycol-molekül- konjugaten aus abbaubarem hydrogel
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
DE69422169D1 (de) Modifizierte proteine und peptide enthaltende pharmazeutische mittel
EA199900751A1 (ru) Фармацевтическая композиция, содержащая лиофилизированные липосомы, включающие инкапсулированный активный ингредиент, практически нерастворимый в воде, и способ получения композиции
DE59407457D1 (de) Blockierung der anlagerung von keimen an menschliche zellen
ATE293700T1 (de) Adenovirus mit glutathion peroxydate gene
IT1299583B1 (it) Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
TR199902575T2 (xx) Peptitler, proteinler ve nükleik asitler için stabil farmasötik uygulama formu.
IE45607L (en) Psychopharmacologically active peptides
ATE211765T1 (de) Neue familie von proteaseinhibitoren und andere biologisch aktive substanzen
RS49520B (sr) Antimikrobno aktivne smeše
KR930004326A (ko) 콘드로모듈린-ii 단백질
DE69804674D1 (de) Liposomen mit mehrfach verzweigten peptidkonstruktionen zur verwendung gegen hiv
SE9904132D0 (sv) Pharmaceutical composition for treatment of diarrhea
IT1251961B (it) Peptidi che rappresentano permutazioni della sequenza del mastoparano
MX9604539A (es) Aminoacidos modificados para la distribucion de farmaco.
KR970058722A (ko) 항진균 활성을 갖는 펩타이드
TH18599EX (th) ยาที่เป็นโปรตีนและเพทไทด์ดัดแปลง
TH18599A (th) ยาที่เป็นโปรตีนและเพทไทด์ดัดแปลง

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee